




Plexxikon

Gideon E. Bollag, PhD

Chief Biologist



Dr. Bollag transitioned to a part-time role as chief biologist in July 2021, having served as chief executive officer since 2013. Previously, he had served as senior vice president of research and vice president of discovery biology. Dr. Bollag joined Plexxikon in 2002, and was instrumental in the discovery and development of both Turalio® and Zelboraf®, Plexxikon's FDA-approved drugs. Prior to Plexxikon, he helped build drug discovery capabilities at Syrrx, Inc., where he was the director of cellular pharmacology. Before Syrrx, he held escalating positions at Onyx Pharmaceuticals, initially as one of the founding scientists and eventually senior director of small molecule therapeutics. While there, Dr. Bollag was involved in the Onyx collaboration with Bayer to discover BAY 43-9006 (Nexavar), now an approved cancer treatment. Prior to Onyx, Dr. Bollag held various scientific positions at Cetus, Inc. Dr. Bollag earned his PhD in biochemistry from the University of California, Berkeley.